Ubamatamab (REGN4018) is a human bispecific antibody that binds mucin 16 (MUC16), a glycoprotein highly expressed in ovarian cancer cells, and the CD3 receptor on T cells, with the goal of inducing T-cell activation to kill ovarian cancer cells [47]. This evidence concerns the gene MUC16 and ovarian carcinoma.